Seelos Therapeutics, Inc.

OTCPK:SEEL.Q Stock Report

Market Cap: US$136.0

Seelos Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Seelos Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth14.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Oct 04

Seelos: Data This Year Is Critical

Summary Seelos has an interesting drug platform. They are planning to release critical data this year. Their cash position was not good, but has been recently bolstered with a market offering. I covered Seelos (SEEL) twice before, and I see from my notes that I also had a detailed communication with company management in order to better understand the company. Despite my initial interest, my plan to take a pilot position in the company did not materialize. This has nothing to do with Seelos specifically, and more to do with the terrible market conditions we saw in the early months of 2022. However, that turned out to be a good thing, because SEEL has mostly traded down in 2022, with a recovery obtaining just in the last couple of months. Seelos makes therapeutic medicines using psychedelic drugs. It also has gene therapy programs. The company has two assets in human trials, SLS-002 targeting ASIB-MDD or acute suicidal ideation and behavior in major depressive disorder, and SLS-005 targeting Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. This last one has a pivotal phase 2/3 trial ongoing since Q1 2022, and also a second pivotal trial in Spinocerebellar Ataxia ((SCA)) which commenced in Q2. Nearest data drop is, however, from SLS-002, which will have a proof of concept study's part 2 data in 2H. An important thing that transpired in July was that the FDA agreed to consider the part 2 study - a large, double-blind, randomized trial - as registrational. That means, the company should be able to submit an NDA in the early months of 2023, and get a PDUFA by the end of 2023. This immediately enhances the value of SEEL. The part 1 data for SLS-02 was quite strong. From the company presentation: All doses judged to be safe and well tolerated with no new or unique safety signals No serious adverse events (SAEs) and all AEs were transient and clinically manageable Expected transient increase in Clinician Administered Dissociative State Scale (CADSS) scores at the higher dose groups (75 mg and 90mg) correlated with Cmax (~40 mins), that resolved with mean values < 4 points at one hour All subjects had a CADSS score < 4 points at two hours Expected mild and transient increase in blood pressure from 30 to 90 minutes post dose, all mean values remained within normal limits, and resolved without intervention Across 4 scales used to measure suicidal ideation, SLS-02 showed strong clinical improvements, as follows: BASELINE (n=17) DAY 1 (n=17) DAY 16 (n=14) MADRS (0-60 scale, ≤12 is remission) 39.4 14.5 7.4 CGIS-SI/B (1-5 scale, 1=not at all, 5=extremely suicidal) 3.8 1.6 1.1 S-STS (0-52 scale, higher score equated to higher suicidality) 22.4 1.7 0.0 PGIS-SI/B (1-5 scale, 1=not present, 5=extremely severe) 3.5 1.6 1.0 MADRS Item-10 (0-6 scale, ≤3 is defined as a response) 5.2 0.8 0.1
Seeking Alpha • Aug 24

Seelos wins Parkinson’s research grant for gene therapy program

Clinical-stage biopharma, Seelos Therapeutics, Inc. (NASDAQ:SEEL), announced Wednesday that the Michael J. Fox Foundation, the world's largest nonprofit funder of Parkinson's research, has selected the company for a grant to advance its lead program for gene therapy candidate SLS-004. With no currently approved therapies to prevent the disease or end its progression, PD remains the world's second most prevalent neurodegenerative disorder. SLS-004 uses CRISPR-dCas9 gene editing to modulate the expression of the SNCA gene, which is thought to be a very significant genetic risk factor for Parkinson's disease (PD). "The selection of SLS-004 to receive grant funding from The Michael J. Fox Foundation is a strong validation of our program and should significantly raise the profile of our program," SEEL's Chief Executive Raj Mehra remarked. Read: In 2021, SEEL announced data for SLS-004 using a rodent model.
Seeking Alpha • Dec 22

Seelos: FDA Action Makes It Highly Attractive

Seelos received communication from the FDA that its part 2 study will be considered registrational. This derisks the company considerably, although the only efficacy data we have so far is from an open label trial. I am considering a pilot position in this stock.
Seeking Alpha • Oct 01

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

Buying volume has increased a lot in recent sessions. The company's SLS-002 offering has been demonstrating good results. Investors are becoming attracted due to the high unmet need in this area. We are looking at selling puts here which is the percentage play in SEEL at present.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Seelos Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:SEEL.Q - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202424-13-13N/A
3/31/20242-27-18-18N/A
12/31/20232-38-24-24N/A
9/30/20232-51-35-35N/A
6/30/20231-81-40-40N/A
3/31/20231-73-55-55N/A
12/31/2022N/A-74-62-62N/A
9/30/2022N/A-82-67-67N/A
6/30/2022N/A-73-66-66N/A
3/31/2022N/A-61-55-55N/A
12/31/2021N/A-66-49-49N/A
9/30/2021N/A-45-34-34N/A
6/30/2021N/A-39-28-28N/A
3/31/2021N/A-33-26-26N/A
12/31/2020N/A-19-21-21N/A
9/30/2020N/A-23-23-23N/A
6/30/20200-22-21-21N/A
3/31/20200-21-18-18N/A
12/31/20190-51-19-19N/A
9/30/20190-42-15-15N/A
6/30/2019N/A-40-12-12N/A
3/31/2019N/A-38-9-9N/A
12/31/2018N/A-3-2-2N/A
9/30/2018N/A-3-1-1N/A
6/30/2018N/A-2-1-1N/A
3/31/2018N/A-2N/A-1N/A
12/31/2017N/A-12N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SEEL.Q's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if SEEL.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SEEL.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SEEL.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SEEL.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SEEL.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/18 12:07
End of Day Share Price 2026/06/01 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Seelos Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Mayank MamtaniB. Riley Securities, Inc.
Thomas ShraderBTIG